Intellia Therapeutics (NTLA) Return on Capital Employed (2016 - 2026)
Intellia Therapeutics' (NTLA) quarterly Return on Capital Employed came in at 58.11% in Q1 2026, down 267.0% year-on-year from 34.8% in Q1 2025, and down 2.76% on a QoQ basis from 56.55% in Q4 2025.
Intellia Therapeutics (NTLA) Return on Capital Employed (2016 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has 11 years of Return on Capital Employed data on file, last reported at 58.11% in Q1 2026.
- On a quarterly basis, Return on Capital Employed fell 267.0% year-over-year to 58.11% in Q1 2026; TTM through Mar 2026 was 58.11%, a 267.0% decrease from a year earlier, with the FY2025 full-year figure at 48.32%, down 125.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 58.11%, down from 56.55% in the prior quarter.
- Over the last five years, Return on Capital Employed for NTLA reached as high as 31.19% in Q1 2023 and fell as low as 60.45% in Q2 2025.
- Historically, Return on Capital Employed has averaged 46.25% across 5 years, with a median of 44.54% in 2023.
- Across the five-year window, Return on Capital Employed tumbled 1898 bps in 2022 and jumped 359 bps in 2023, its largest moves.
- Year by year, Return on Capital Employed stood at 38.97% in 2022, then slipped by 14 bps to 44.54% in 2023, then slipped by 12 bps to 49.87% in 2024, then fell by 13 bps to 56.55% in 2025, then slipped by 3 bps to 58.11% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 58.11% in Q1 2026, 56.55% in Q4 2025, and 58.5% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Intellia Therapeutics | 1.32 Bn | 1.32 Bn | - | -58.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -58.11% |
| Dec 31, 2025 | -56.55% |
| Sep 30, 2025 | -58.50% |
| Jun 30, 2025 | -60.45% |
| Mar 31, 2025 | -55.44% |
| Dec 31, 2024 | -49.87% |
| Sep 30, 2024 | -49.94% |
| Jun 30, 2024 | -46.77% |
| Mar 31, 2024 | -43.75% |
| Dec 31, 2023 | -44.54% |
| Sep 30, 2023 | -40.75% |
| Jun 30, 2023 | -36.19% |
| Mar 31, 2023 | -31.19% |
| Dec 31, 2022 | -38.97% |
| Sep 30, 2022 | -44.34% |
| Jun 30, 2022 | -38.24% |
| Mar 31, 2022 | -32.58% |
| Dec 31, 2021 | -22.53% |
| Sep 30, 2021 | -25.37% |
| Jun 30, 2021 | -29.96% |